Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Monte Rosa Therapeutics (GLUE) Non Operating Investment Income (2023)

Historic Non Operating Investment Income for Monte Rosa Therapeutics (GLUE) over the last 1 years, with Q1 2023 value amounting to -$131000.0.

  • Monte Rosa Therapeutics' Non Operating Investment Income changed N/A to -$131000.0 in Q1 2023 from the same period last year, while for Dec 2023 it was -$131000.0, marking a year-over-year change of. This contributed to the annual value of -$131000.0 for FY2023, which is N/A changed from last year.
  • Latest data reveals that Monte Rosa Therapeutics reported Non Operating Investment Income of -$131000.0 as of Q1 2023.
  • Monte Rosa Therapeutics' Non Operating Investment Income's 5-year high stood at -$131000.0 during Q1 2023, with a 5-year trough of -$131000.0 in Q1 2023.